Ryan F. Relich

Ryan F. Relich

Auto-generated profile, based on publicly available information

Ryan F. Relich

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in Journal of Clinical Virology
Verified
Journal Article
Open access
KGKenneth Gavina
Kenneth Gavina
LFLauren C. Franco
Lauren C. Franco
HKHaseeba Khan
Haseeba Khan
JLJohn-Paul Lavik
John-Paul Lavik
RRRyan F. Relich
Ryan F. Relich
Molecular point-of-care (POC) tests offer high sensitivity, rapid turnaround times, relative ease of use, and the convenience of laboratory-grade testing in the absence of formal laboratory spaces and equipment, making them appealing options for infectious disease diagnosis in resource-limited settings. In this review, we discuss the role and potential of molecular POC tests in resource-limited settings and their associated logistical challenges. We discuss U.S. Food and Drug Administration approval, Clinical Laboratory Improvement Amendments complexity levels, and the REASSURED criteria as a starting point for assessing options currently available inside and outside of the United States. We then present POC tests currently in research and development phases that have potential for commercialization and implementation in limited-resource settings. Finally, we review published studies that have assessed the clinical impact of molecular POC testing in limited- and moderate-resource settings.

1 June 2017 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
RRRyan F. Relich
Ryan F. Relich
MLMichael Loeffelholz
Michael Loeffelholz

12 June 2024 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
LFLauren C. Franco
Lauren C. Franco
MAMahmoud Ahmed
Mahmoud Ahmed
CKChristopher G. Kendra
Christopher G. Kendra
RSR. Matthew Sperling
R. Matthew Sperling
KBKayla Van Benten
Kayla Van Benten
KGKenneth Gavina
Kenneth Gavina
Candida auris is a multidrug-resistant opportunistic fungal pathogen capable of causing serious infections and healthcare-associated outbreaks. Screening for colonization with C. auris has become routine and is recommended in many hospitals and healthcare facilities as an infection control and prevention strategy. Subsequently, and since there are currently no FDA-approved tests for this purpose, clinical microbiology laboratories have become responsible for developing protocols to detect C. auris using axial and inguinal screening swabs. In a College of American Pathologists-accredited large academic healthcare center setting, we implemented a laboratory-developed nucleic-acid amplification test for the detection of C. auris DNA. Our test validation evaluated the performance of the DiaSorin C. auris primer set used in a real-time qualitative PCR assay on the LIAISON MDX thermocycler with the Simplexa Universal Disc. The assay was highly sensitive and specific, with a limit of detection of 1–2 CFU/reaction, with no observed cross-reactivity with other Candida spp., bacterial skin commensal organisms or commonly encountered viruses. When run in parallel with a culture-based detection method, the PCR assay was 100% sensitive and specific. The assay was precise, with low variability between replicates within and between runs. Lastly, pre-analytical factors, including swab storage time, temperature, and transport media, were assessed and found to have no significant effect on the detection of C. auris at variable concentrations. Taken together, this study expands the available options for nucleic acid detection of C. auris and characterizes pre-analytical factors for implementation in both high- and low-volume laboratory settings. IMPORTANCE : This study overviews the validation and implementation of a molecular screening tool for the detection of Candida auris in a College of American Pathologist-accredited clinical laboratory. This molecular laboratory-developed test is both highly sensitive and specific and has significant health-system cost-savings associated with significantly reduced turn-around-time compared to traditional standard-of-care culture-based work up. This method and workflow is of interest to support clinical microbiology diagnostics and to help aid in hospital inpatient, and infection prevention control screening.

1 December 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
RRRyan F Relich
Ryan F Relich
RHRomney M Humphries
Romney M Humphries
HMH Reid Mattison
H Reid Mattison
JMJessica E Miles
Jessica E Miles
ESEdward R Simpson
Edward R Simpson
MMM May
M May
Francisella philomiragia is a very uncommon pathogen of humans. Diseases caused by it are protean and have been reported largely in near-drowning victims and those with chronic granulomatous disease. We present a case of F. philomiragia pneumonia with peripheral edema and bacteremia in a renal transplant patient and review the diverse reports of F. philomiragia infections.

26 January 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
RRRyan F Relich
Ryan F Relich
MLMichael J Loeffelholz
Michael J Loeffelholz
The classification of viruses remains relevant to several disciplines, including clinical virology. Since the original publication of this review in 2019, many known viruses have undergone taxonomic revisions, and several novel human and animal viruses have been described.

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
KGKenneth Gavina
Kenneth Gavina
LFLauren C. Franco
Lauren C. Franco
Christopher RobinsonChristopher Robinson
Christopher Robinson
WHWeston Hymas
Weston Hymas
GLGuang-Sheng Lei
Guang-Sheng Lei
RRRyan F. Relich
Ryan F. Relich
From the onset of the COVID-19 pandemic, the demand for SARS-CoV-2 testing has resulted in an explosion of analytical tests with very different approaches and designs. The variability in testing modalities, compounded by the lack of available commercial reference materials for standardization early in the pandemic, has led to several challenges regarding data harmonization for viral quantitation.